Search 

Focus on cancer,intestinal disease

Kitov Pharma (NASDAQ:KTOV) is a clinical stage biopharmaceutical
company advancing first in class oncology therapies. We currently have one FDA
approved drug, Consensi™, and two oncology therapeutic candidates, CM-24 and NT-219:

• CM-24 is a clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with high potential to treat multiple oncology indications. CEACAM1 is associated with angiogenesis, is an
inter-cellular adhesion regulator and acts as a TIM-3 activator. High CEACAM1 expression is known to be associated with poor disease prognosis in a number of tumor types. Thus, blocking CEACAM1 with CM24 is associated with anti-angiogenic, immune access, and checkpoint release mechanisms. In a phase I
clinical study, CM-24 demonstrated a good safety profile and promising efficacy signals. We are developing CM-24 in a clinical collaboration with Bristol
Myers-Squibb for Phase 1/2 trial combining CM-24 with nivolumab in NSCLC and pancreatic cancer patients expressing high CEACAM1 levels.

• NT-219 is a first-in-class, dual inhibitor small molecule targeting IRS 1/2 and STAT3, two key signal transducers that promote cancer drug resistance. In preclinical studies, NT-219 demonstrated outstanding
efficacy in preventing acquired resistance and reversing tumor resistance when administered as a monotherapy and in combination with various oncology therapies. We are initiating first-in-man clinical trials with NT219, both as monotherapy and in combination with cetuximab (Erbitux™), with plans to expand combination studies in patients with recurrent or metastatic SCCHN cancer during 2020.

Kymeris Therapeutics (Canada) has exlusive license to a ground-breaking cell-based immunotherapeutic product for clinical development in cancer. This multivalent anti-cancer platform integrates multiple mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses encoded biodrugs in the cancer - but not systemically.

*  We are seeking partners with small molecule or antibody (or any encodable peptide or protein) that would have an enabling platform compared to intravenous or intratumoral formulations.

*  We are also seeking strategic investors in the platform that has extremely high potential in future products, adaptable against almost any solid cancer.

------------------------------------------------------------------

The platform can enable, or enhance, additional small molecule, antibody, peptide or cytokine agents.  It is a preclinical late-stage firm that has discovered and developed a First-in-Class immunotherapeutic platform based on non-pathogenic eukaryotes (nucleated cells, non-viral, non-bacterial). Our platform is original with the first scientific paper just published in November 2020 by the Journal of Immunotherapy of Cancer (BMJ), and our first scientific presentation at the 2020 Annual Meeting of the SITC where we presented recent report on a derivative that secreted human IL-15 within tumor, but devoid of serum detection of the cytokine.

The platform would be a paradigm shift from "reductive" (targeted, mono-mechanism) approaches, and can be encoded with additional molecular therapies to more comprehensively face the complex of solid cancer defenses. Encoding any biological agent (small molecule, antibody, antigen, cytokine...), could enable that agent for a wider scope of applications,  enhanced effect and much safer profile.  In addition, the platform shows abscopal effect, an ability to reach tumors after administration from a distance (subcutaneous or mucosal).

The platform has shown the following characteristics:

1. Tumor-tropism / Cancer-agnostic. Homing to tumor occurred in the absence of a cancer antigen marker (TAA or TSA), and may even work in tumors that are not easily "targetable", such as "cold", lacking cancer markers, heterogeneic or mutating tumors. One oncologist remarked, "This turns "cold" tumors "hot" ".The agents have had effect at distance from tumor site when administered subcutaneously or mucosally. 

 2. Tumor-infiltration + TME counteraction. The agents bear a specialized "universal key" to gain entry into mammalian cell in an active process; no specific  receptor needed. In addition, the agents are able to reprogram tolerogenic cells into a state of immune competence i.e. to overcome cancer-induced immune suppression within the tumor.

3. Intra-cancer delivery of any payload/s. Obligate intracellular microbes, the agents infect cancer cells and replicate, expressing encoded biodrugs. The replication continues as long as there is cancer tissue to infect and/or the TME has not been disabled.  Any agents outside of the TME were naturally cleared in under 10 days.